Edwards Lifesciences (EW): financials, SEC filings and peers
Edwards Lifesciences (EW) is a health care equipment company in the Health Care sector of the S&P 500, headquartered in Irvine, California.
It was founded in 1958 and joined the S&P 500 on April 1, 2011.
Its fiscal year ends in December, and its shares trade on the NYSE.
In its SEC filings it is classified as “Orthopedic, Prosthetic & Surgical Appliances & Supplies”.
Edwards Lifesciences at a glance
- Revenue (12 months)
- $6.5B
- Revenue growth
- +14.6%
- Operating margin
- 22.3%
- Net income (12 months)
- $1.0B
- Free cash flow (12 months)
- $1.4B
- Cash
- $2.9B
- Debt
- $599M
- Diluted EPS (12 months)
- $1.74
Twelve months to June 30, 2026, from the 10-Q filed August 4, 2026.
Latest twelve months
Over the twelve months to June 30, 2026, Edwards Lifesciences reported revenue of $6.5 billion, up 14.6% from a year earlier.
Its operating margin was 22.3%, down 3.6 percentage points from a year earlier: for every $100 of sales, about $22 was left as operating profit.
Net income was $1.0 billion (15.4% of revenue), 75.8% lower than a year earlier.
Profit fell while sales grew, which usually points to higher costs, heavier investment or one-time items. The filings explain which.
Operating cash flow was $1.7 billion and capital spending $287 million, leaving free cash flow of $1.4 billion (22.0% of revenue).
At the end of the period it held $2.9 billion in cash and $599 million in debt, a net cash position of $2.3 billion.
The diluted share count fell 1.8% in a year, typically the result of buybacks.
Five-year trend
- Revenue went from $4.4 billion in fiscal 2020 to $6.1 billion in fiscal 2025, about 6.7% a year.
- Revenue has grown for 3 fiscal years in a row.
- Operating margin has been steady, around 20.8%.
- Free cash flow was positive in each of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $5.2B | $4.5B | $5.0B | $5.4B | $6.1B |
| Revenue growth | 19.3% | -14.7% | 12.2% | 8.6% | 11.5% |
| Operating margin | 32.3% | 33.6% | 26.1% | 25.3% | 20.8% |
| Net income | $1.5B | $1.5B | $1.4B | $4.2B | $1.1B |
| Free cash flow | $1.4B | $974M | $643M | $290M | $1.3B |
| Diluted EPS | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 |
Fiscal years as reported in Edwards Lifesciences’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 8-K filed August 28, 2026 — Executive or director change
- 10-Q filed August 4, 2026 — quarterly report
- 8-K filed July 23, 2026 — Earnings results
- 8-K filed May 8, 2026 — Executive or director change; Shareholder vote results
- 10-Q filed May 6, 2026 — quarterly report
- 8-K filed May 4, 2026 — Executive or director change; Regulation FD disclosure
- 8-K filed April 23, 2026 — Earnings results
Companies like Edwards Lifesciences
Other S&P 500 companies in Health Care Equipment:
- ABTAbbott LaboratoriesNorth Chicago, Illinois
- BAXBaxter InternationalDeerfield, Illinois
- BDXBecton DickinsonFranklin Lakes, New Jersey
- BSXBoston ScientificMarlborough, Massachusetts
- DXCMDexcomSan Diego, California
- GEHCGE HealthCareChicago, Illinois
- IDXXIdexx LaboratoriesWestbrook, Maine
- ISRGIntuitive SurgicalSunnyvale, California
More from Health Care
Questions about Edwards Lifesciences
Is Edwards Lifesciences's revenue growing?
Yes. Revenue for the twelve months to June 30, 2026 was $6.5 billion, up 14.6% from a year earlier, according to its SEC filings.
Is Edwards Lifesciences profitable?
Yes. It earned $1.0 billion in net income over the twelve months to June 30, 2026, a net margin of 15.4%.
Does Edwards Lifesciences have more cash or more debt?
At June 30, 2026 it had $2.9 billion in cash and $599 million in debt, so more cash than debt.
When did Edwards Lifesciences last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on August 4, 2026.
Which companies are similar to Edwards Lifesciences?
In the S&P 500, Edwards Lifesciences is grouped in Health Care Equipment within the Health Care sector. Abbott Laboratories (ABT), Baxter International (BAX), Becton Dickinson (BDX), Boston Scientific (BSX), Dexcom (DXCM) are in the same group.
Understand the numbers
Source: Edwards Lifesciences’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.